Top-line data from the pivotal KEYNOTE-826 trial show Merck & Co., Inc.’s checkpoint inhibitor Keytruda (pembrolizumab) improves overall survival and progression free survival when used as part of first-line therapy for metastatic cervical cancer, supporting the move of the checkpoint inhibitor to earlier lines of therapy in the condition.
There is an unmet need for drugs to treat metastatic cervical cancer, which often affects young and middle-aged women. “KEYNOTE-826 is the first study to show positive results for immunotherapy...